CSR Report

The report describes Galapagos' 2020 approval and launch of filgotinib in Europe and Japan. It reports a 1,489-person group workforce, including 898 women, and four female members of an eight-member supervisory board. The company implemented an Animal Welfare Committee and reports 93.5% completion of Code training. It also describes an EHS management system based on ISO 14001 and ISO 45001, while reporting two lost-time incidents at three research centers.